Medication Management for Peripartum Cardiomyopathy During Pregnancy

Contraindicated Medications

ACE inhibitors, ARBs, and direct renin inhibitors should not be used because they cause serious fetal renal toxicity and are teratogenic. European Society of Cardiology (ESC) guideline 1, 2, 3, 4 – evidence level not specified.
Aldosterone antagonists (e.g., spironolactone, eplerenone) are avoided due to anti‑androgenic effects in early pregnancy and lack of safety data. ESC guideline 1, 2, 3, 4 – evidence level not specified.
Atenolol is not recommended as the β‑blocker of choice in pregnancy. ESC guideline 1 – evidence level not specified.

Hydralazine combined with long‑acting nitrates is the preferred afterload‑reduction regimen during pregnancy, providing effective vasodilation without teratogenic risk. ESC guideline 1, 2, 3, 4 – evidence level not specified.

β1‑selective β‑blockers (e.g., metoprolol) are safe and indicated for heart‑failure patients when tolerated. ESC guideline 1, 2, 3, 4 – evidence level not specified.
β1‑selective agents are preferred because β2‑blockade could theoretically impair uterine relaxation (anti‑tocolytic effect). ESC guideline 1, 3, 4 – evidence level not specified.
Neonates should be observed for 24–48 hours after delivery for hypoglycaemia, bradycardia, and respiratory depression when the mother received β‑blockers. ESC guideline 1 – evidence level not specified.

Diuretics should be used only when pulmonary congestion is present, to minimise the risk of reduced placental blood flow. ESC guideline 1, 2, 3, 4 – evidence level not specified.
Furosemide and hydrochlorothiazide are the most frequently employed diuretics when needed. ESC guideline 1, 2, 3, 4 – evidence level not specified.

Unfractionated heparin or low‑molecular‑weight heparin (LMWH) are recommended when left‑ventricular ejection fraction (LVEF) is < 35 % because PPCM carries a high thrombo‑embolic risk. ESC guideline 1, 2, 3, 4 – evidence level not specified.
PPCM is a pro‑thrombotic condition with increased incidence of ventricular thrombi, cerebral embolism, and peripheral embolism. ESC guideline 1 – evidence level not specified.
Anti‑Xa levels should be monitored during LMWH therapy to ensure therapeutic anticoagulation. ESC guideline 1 – evidence level not specified.
Warfarin is contraindicated throughout pregnancy due to fetotoxicity. ESC guideline 3, 4 – evidence level not specified.

Dopamine and levosimendan may be used when signs of hypoperfusion or persistent congestion persist despite vasodilators and diuretics. ESC guideline 1 – evidence level not specified.

Immediately after delivery, standard heart‑failure therapy should be instituted: ACE inhibitors or ARBs, continuation of β‑blockers, and addition of aldosterone antagonists. ESC guideline 1 – evidence level not specified.
For breastfeeding mothers, ACE inhibitors such as benazepril, captopril, or enalapril are considered safe for the infant. ESC guideline 1, 2 – evidence level not specified.

Joint cardiac‑obstetric care is essential for women presenting with PPCM during pregnancy. ESC guideline 1 – evidence level not specified.
Urgent delivery may be required regardless of gestational age when the patient exhibits advanced heart failure with hemodynamic instability. ESC guideline 1 – evidence level not specified.
Approximately 50 % of PPCM patients experience spontaneous recovery within the first 6 months, a factor that should inform decisions about advanced therapies. ESC guideline 1, 2 – evidence level not specified.

The European Society of Cardiology recommends hydralazine as the preferred option for managing peripartum cardiomyopathy during pregnancy, due to the contraindication of ACE inhibitors and ARBs 5, 6, 7
ACE inhibitors and ARBs are contraindicated during pregnancy due to serious fetal renal toxicity and teratogenicity, and are classified as FDA Category D, meaning there is positive evidence of human fetal risk 5, 6, 7, 8

Hydralazine, in combination with long-acting nitrates, can be used safely instead of ACE inhibitors/ARBs in patients with peripartum cardiomyopathy during pregnancy, providing vasodilation without the teratogenic risks associated with renin-angiotensin system blockade 5, 6, 7, 9
Beta-1 selective beta-blockers, such as metoprolol, are safe during pregnancy and can be initiated as part of the management plan 5, 6, 7
Diuretics, such as furosemide or hydrochlorothiazide, should be used sparingly only if pulmonary congestion is present, as they can decrease placental blood flow 5, 6, 7

Anticoagulation with unfractionated or low-molecular-weight heparin should be considered if LVEF < 35% due to high thromboembolism risk, and warfarin should be avoided during pregnancy due to fetotoxicity 5, 6, 7
Immediately after delivery, ACE inhibitors can be switched to, such as captopril, enalapril, or benazepril, and beta-blocker therapy should be continued 10
Bromocriptine may be considered for 2-8 weeks postpartum if LVEF < 35% to enhance cardiac recovery, but requires therapeutic anticoagulation due to increased thrombosis risk 10, 11

ACE inhibitors and ARBs should never be used during pregnancy, regardless of heart failure severity, due to unacceptable fetal risks 5, 6, 7, 8
Spironolactone should be avoided during pregnancy due to anti-androgenic effects in the first trimester 5, 6, 7
Over-diuresis should be avoided as it can compromise placental perfusion 5, 6, 7
ICD placement should be deferred for at least 6 months as approximately 50% of PPCM patients show substantial improvement or normalization of LV function within this timeframe 10

Mortality rates range from 1-30% depending on geographic location and access to care 11